Jiangxia Blood Technology

Wuhan Jiangxia Blood Technology is a Chinese biotechnology company specializing in the development and production of blood-derived therapeutics. As a subsidiary of China National Biotec Group (CNBG) under the state-owned Sinopharm, the company gained international recognition for its rapid response to the COVID-19 pandemic. It was the first organization to develop and clinically test COVID-19-specific intravenous immunoglobulin (IVIG) derived from the plasma of recovered patients. The company's core operations include large-scale plasma collection, fractionation, and the manufacturing of specialized biologics for infectious diseases. Based in the Jiangxia District of Wuhan, it serves as a critical hub for China's national biosecurity and emergency medical infrastructure.